This post-hoc subgroup analysis supports that ensifentrine, a dual PDE3/PDE4 inhibitor, provides additional benefit to standard classes of COPD therapy consistent with its novel mechanism of action. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.